Valeant (VRX) August weekly volatility elevated as shares up in premarket on Q2 and outlook
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Valeant Pharma (NYSE: VRX) is recently up $1.55 to $24 in the premarket on backs FY16 revenue guidance of $9.9B-$10.1B, compared to consensus $10.01B. August weekly call option implied volatility is at 147, August is at 109, September is at 84; compared to its 52-week range of 34 to 175.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Valeant Pharma (VRX) Moves Off Lows on Bill Miller Comments
- Facebook (FB) November weekly 140 calls active into Q3 and outlook
- Express Scripts (ESRX) volatility increases on more calls than puts into Q3 and outlook
Create E-mail Alert Related CategoriesOptions, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!